Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
February 06 2023 - 7:00AM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the
Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced the
appointment of J.P. Gabriel as Chief Technical Operations Officer
following the retirement of Jørgen Wittendorff, SVP, Technical
Operations. In this role, J.P. is responsible for Manufacturing,
Process and Analytical Development and Supply Chain.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230206005194/en/
J.P. Gabriel, Chief Technical Operations
Officer, Silence Therapeutics plc. (Photo: Business Wire)
“We are pleased to welcome J.P. to Silence during this very
exciting time,” said Craig Tooman, President and CEO of Silence.
“He brings over 25 years of industry experience in supply chain,
quality assurance and manufacturing that will be critical as we
continue to advance our clinical stage pipeline. We also want to
thank Jørgen for his many contributions to Silence over the
years.”
J.P. Gabriel commented, “Silence has a very promising clinical
pipeline and siRNA technology platform with potential to address
both rare and common genetic diseases. I am grateful for the
opportunity to work with the team to help deliver the pipeline
while continuing to build an effective and agile organization that
is set for growth.”
Mr. Gabriel has over 25 years of international pharmaceutical
industry experience across multiple therapeutic modalities. He has
held leadership roles in Manufacturing, Quality, Validation and
Supply Chain with firms such as Sanofi-Pasteur, Wyeth (now Pfizer)
and Genentech/Roche. He most recently served as SVP, Technical
Operations at Ocugen, which includes AAV gene therapy, vaccine, and
cell therapy development. Before Ocugen, he spent over five years
at Ultragenyx where he was responsible for Biologics and mRNA
manufacturing for programs spanning clinical and commercial stages
of the development lifecycle. Mr. Gabriel holds an Honors B.Sc.
from the University of Guelph in Ontario, Canada and an Advanced
Certificate in Regulatory Affairs from the University of San Diego
in California.
About Silence Therapeutics Silence Therapeutics is
developing a new generation of medicines by harnessing the body’s
natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the
pathology of diseases with significant unmet need. Silence’s
proprietary mRNAi GOLD™ platform can be used to create siRNAs
(short interfering RNAs) that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence’s wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address rare
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements Certain statements made in
this announcement are forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 and
other securities laws, including with respect to the Company’s
clinical and commercial prospects, regulatory approvals of the
Company’s product candidates, potential partnerships or
collaborations or payments under new and existing collaborations,
the initiation or completion of the Company’s clinical trials and
the anticipated timing or outcomes of data reports from the
Company’s clinical trials. These forward-looking statements are not
historical facts but rather are based on the Company's current
assumptions, beliefs, expectations, estimates and projections about
its industry. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including those risks identified in the Company’s most recent
Admission Document and its Annual Report on Form 20-F filed with
the U.S. Securities and Exchange Commission (the “SEC”) on March
17, 2022. The Company cautions security holders and prospective
security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230206005194/en/
Enquiries: Silence Therapeutics plc Gem Hopkins,
Head of IR and Corporate Communications ir@silence-therapeutics.com
+1 (646) 637-3208
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jul 2023 to Jul 2024